3 results match your criteria: "Samara Regional Center for Prevention and Control of AIDS and Infectious Diseases.[Affiliation]"
Correction to: Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
Clin Drug Investig
March 2021
Department of Infectious Diseases, Military Medical Academy, St Petersburg, Russian Federation.
Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
Clin Drug Investig
March 2018
Department of Infectious Diseases, Military Medical Academy, St Petersburg, Russian Federation.
Unlabelled: BACKGROUND AND OBJECTIVES: The efficacy of < 12 weeks of hepatitis C virus (HCV) treatment in patients co-infected with HCV and human immunodeficiency virus type 1 (HIV-1) has not been established. We assessed the efficacy and safety of ledipasvir-sofosbuvir for 8 weeks in HCV mono-infected and HCV/HIV-1 co-infected patients.
Methods: We enrolled patients mono-infected with genotype 1 HCV or co-infected with HCV and HIV-1 who were HCV treatment-naive and did not have cirrhosis.
Aim: To evaluate the effectiveness of combined use of the imiquimod 5% cream and vaccination against human papillomavirus (HPV) using a quadrivalent recombinant vaccine to achieve long-term clinical remission of chronic HPV infection manifested by anogenital warts.
Material And Methods: The study comprised 36 patients, including 22 men, aged 26.4+/-4.